表观遗传学和控制瘤血管生成在黑色素瘤:更新与治疗影响
Gerardo Cazzato1, Nicoletta Sgarro1, Nadia Casatta2
1Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", 70124 Bari, Italy.
Cancers
|August 29, 2024
概括
诸如DNA甲基化和基因质变化的表观遗传修饰调节了黑色素瘤中的血管形成. 针对这些表观遗传机制提供了一个有希望的治疗策略,以抑制黑色素瘤的进展和转移.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 血管新生对于黑色素瘤的生长和传播至关重要.
- 表观遗传修饰显著影响血管新生通路.
研究的目的:
- 审查表观遗传机制如何调节黑色素瘤中的血管生成.
- 探索针对抗血管性疗法的表观遗传修饰的治疗策略.
主要方法:
- 对有关黑色素瘤血管生成表观遗传调节的当前文献的综述.
- 对DNA甲基化,基因组修饰和非编码RNA的作用进行分析.
- 对表观遗传药物的临床前数据的检查.
主要成果:
- DNA甲基化使抑制剂 (例如,血栓松丁-1) 沉默,并促进因子 (例如,VEGF).
- 基因组基因修饰 (乙化,甲基化) 改变血管生成相关的基因表达.
- 像miR-9和miR-210这样的非编码RNAs (miRNAs) 调节血管新生通路.
结论:
- 表观遗传机制是黑色素瘤血管生成的关键调节者.
- 表观遗传药物 (DNMT和HDAC抑制剂) 显示出治疗潜力.
- 调节非编码RNA提供了新的抗血管生成策略.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Mechanism of Angiogenesis
5.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.4K
Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493


